loading
전일 마감가:
$118.44
열려 있는:
$116.06
하루 거래량:
3.64M
Relative Volume:
0.54
시가총액:
$151.04B
수익:
$28.80B
순이익/손실:
$6.31B
주가수익비율:
24.22
EPS:
5.0273
순현금흐름:
$9.37B
1주 성능:
+0.63%
1개월 성능:
+9.64%
6개월 성능:
+14.23%
1년 성능:
+37.02%
1일 변동 폭
Value
$114.02
$121.91
1주일 범위
Value
$114.02
$121.91
52주 변동 폭
Value
$86.08
$124.61

길리어드 사이언스 Stock (GILD) Company Profile

Name
명칭
Gilead Sciences Inc
Name
전화
(650) 574-3000
Name
주소
333 LAKESIDE DR, FOSTER CITY, CA
Name
직원
17,600
Name
트위터
@GileadSciences
Name
다음 수익 날짜
2025-02-11
Name
최신 SEC 제출 서류
Name
GILD's Discussions on Twitter

GILD을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - General icon
GILD
Gilead Sciences Inc
121.73 146.96B 28.80B 6.31B 9.37B 5.0273
Drug Manufacturers - General icon
LLY
Lilly Eli Co
847.54 757.06B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
188.25 455.48B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
218.26 403.13B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
122.69 235.26B 54.45B 14.42B 16.89B 7.333
Drug Manufacturers - General icon
MRK
Merck Co Inc
84.67 215.51B 63.43B 16.42B 14.72B 6.4861

길리어드 사이언스 Stock (GILD) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-08-19 업그레이드 Daiwa Securities Neutral → Outperform
2025-08-08 업그레이드 Truist Hold → Buy
2025-07-25 업그레이드 Needham Hold → Buy
2025-04-22 재개 Cantor Fitzgerald Overweight
2025-03-04 재확인 Oppenheimer Outperform
2025-02-18 업그레이드 Deutsche Bank Hold → Buy
2025-02-13 업그레이드 DZ Bank Hold → Buy
2025-01-10 업그레이드 Morgan Stanley Equal-Weight → Overweight
2024-12-10 재개 BofA Securities Buy
2024-11-15 개시 Wolfe Research Outperform
2024-11-14 개시 Citigroup Buy
2024-11-08 다운그레이드 Maxim Group Buy → Hold
2024-10-21 업그레이드 Leerink Partners Market Perform → Outperform
2024-10-17 개시 Bernstein Outperform
2024-10-07 업그레이드 Wells Fargo Equal Weight → Overweight
2024-07-08 업그레이드 Raymond James Mkt Perform → Outperform
2024-05-01 재확인 Maxim Group Buy
2024-04-24 업그레이드 HSBC Securities Reduce → Hold
2024-02-22 다운그레이드 Truist Buy → Hold
2023-11-09 개시 Deutsche Bank Hold
2023-09-08 업그레이드 BofA Securities Neutral → Buy
2023-09-06 개시 HSBC Securities Reduce
2023-07-24 재확인 Barclays Equal Weight
2023-05-16 업그레이드 BMO Capital Markets Market Perform → Outperform
2023-04-28 재개 Piper Sandler Overweight
2023-01-03 다운그레이드 RBC Capital Mkts Outperform → Sector Perform
2022-12-13 재개 BofA Securities Neutral
2022-12-09 다운그레이드 DZ Bank Buy → Hold
2022-10-31 업그레이드 Barclays Underweight → Equal Weight
2022-10-28 재확인 BMO Capital Markets Market Perform
2022-10-28 재확인 Cowen Outperform
2022-10-28 재확인 JP Morgan Overweight
2022-10-28 재확인 Jefferies Buy
2022-10-28 업그레이드 Piper Sandler Neutral → Overweight
2022-10-28 재확인 RBC Capital Mkts Outperform
2022-10-28 업그레이드 Truist Hold → Buy
2022-10-28 재확인 Wells Fargo Equal Weight
2022-10-04 업그레이드 JP Morgan Neutral → Overweight
2022-07-13 개시 Cantor Fitzgerald Neutral
2022-05-23 개시 SVB Leerink Mkt Perform
2022-02-28 다운그레이드 BMO Capital Markets Outperform → Market Perform
2022-02-02 재확인 BMO Capital Markets Outperform
2022-02-02 재확인 BofA Securities Neutral
2022-02-02 재확인 RBC Capital Mkts Outperform
2022-02-02 재확인 Truist Hold
2022-02-02 재확인 Wells Fargo Equal Weight
2022-01-28 업그레이드 Argus Hold → Buy
2022-01-06 다운그레이드 Morgan Stanley Overweight → Equal-Weight
2021-12-09 재개 Wells Fargo Equal Weight
2021-12-06 개시 Goldman Neutral
2021-11-19 업그레이드 BMO Capital Markets Market Perform → Outperform
2021-11-19 재개 Piper Sandler Neutral
2021-10-20 재개 Cowen Outperform
2021-07-30 재확인 BMO Capital Markets Market Perform
2021-07-30 재확인 RBC Capital Mkts Outperform
2021-04-01 업그레이드 Bernstein Mkt Perform → Outperform
2021-03-30 업그레이드 Redburn Neutral → Buy
2021-01-19 업그레이드 Morgan Stanley Equal-Weight → Overweight
2021-01-04 업그레이드 Guggenheim Neutral → Buy
2020-11-03 재개 Morgan Stanley Equal-Weight
2020-10-28 개시 UBS Neutral
2020-09-30 재개 Jefferies Buy
2020-09-15 업그레이드 Maxim Group Hold → Buy
2020-07-31 재확인 Credit Suisse Neutral
2020-07-31 재확인 Morgan Stanley Equal-Weight
2020-07-31 재확인 Piper Sandler Overweight
2020-07-31 재확인 RBC Capital Mkts Outperform
2020-07-31 재확인 SunTrust Hold
2020-07-31 재확인 Wells Fargo Equal Weight
2020-07-20 업그레이드 Credit Suisse Underperform → Neutral
2020-06-03 업그레이드 SVB Leerink Mkt Perform → Outperform
2020-05-26 업그레이드 SunTrust Sell → Hold
2020-05-01 다운그레이드 JP Morgan Overweight → Neutral
2020-05-01 다운그레이드 Raymond James Outperform → Mkt Perform
2020-05-01 다운그레이드 SunTrust Hold → Sell
2020-04-27 다운그레이드 UBS Buy → Neutral
2020-04-20 다운그레이드 BMO Capital Markets Outperform → Market Perform
2020-04-20 다운그레이드 Wells Fargo Overweight → Equal Weight
2020-04-17 다운그레이드 CFRA Hold → Sell
모두보기

길리어드 사이언스 주식(GILD)의 최신 뉴스

pulisher
10:11 AM

HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead - Enidnews.com

10:11 AM
pulisher
10:03 AM

Does Gilead Sciences Offer Strong Value After Breakthroughs in Antiviral Treatments? - simplywall.st

10:03 AM
pulisher
09:16 AM

Gilead GILD Q3 2025 Earnings Call Transcript - AOL.com

09:16 AM
pulisher
09:01 AM

Gilead Sciences (GILD) Maintains Dividend, Adjusts 2025 Outlook - GuruFocus

09:01 AM
pulisher
08:57 AM

Gilead Sciences (GILD) Acquires Key Assets from HOOKIPA Pharma - GuruFocus

08:57 AM
pulisher
08:52 AM

Hookipa Pharma Completes Sales of HBV and HIV Assets to Gilead Sciences - MarketScreener

08:52 AM
pulisher
08:51 AM

Gilead 3rd-qtr EPS beats expectations - The Pharma Letter

08:51 AM
pulisher
08:45 AM

GILD Receives 'Buy' Rating Reiteration from Needham | GILD Stock News - GuruFocus

08:45 AM
pulisher
08:28 AM

Impact Partnership Wealth LLC Grows Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat

08:28 AM
pulisher
08:12 AM

HOOKIPA Pharma Inc. Completes Asset Sale of HB-400 and HB-500 Programs to Gilead Sciences - Quiver Quantitative

08:12 AM
pulisher
08:00 AM

HOOKIPA Pharma (OTC: HOOK) closes sale of HB-400 and HB-500 program assets to Gilead - Stock Titan

08:00 AM
pulisher
07:53 AM

Gilead Still Hungry For Deals as HIV Portfolio Grows, Veklury Crashes - BioSpace

07:53 AM
pulisher
07:38 AM

Amalgamated Bank Buys 22,916 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

07:38 AM
pulisher
07:10 AM

Goldman Sachs Adjusts Price Target on Gilead Sciences to $110 From $108, Maintains Neutral Rating - MarketScreener

07:10 AM
pulisher
07:10 AM

Morgan Stanley Adjusts Price Target on Gilead Sciences to $147 From $143, Maintains Overweight Rating - MarketScreener

07:10 AM
pulisher
07:09 AM

JPMorgan Adjusts Price Target on Gilead Sciences to $150 From $145, Maintains Overweight Rating - MarketScreener

07:09 AM
pulisher
07:08 AM

RBC Capital Adjusts Price Target on Gilead Sciences to $105 From $100, Maintains Sector Perform Rating - MarketScreener

07:08 AM
pulisher
06:41 AM

Arkadios Wealth Advisors Grows Stake in Gilead Sciences, Inc. $GILD - MarketBeat

06:41 AM
pulisher
06:19 AM

Kuick Research Releases Landmark Study On US Orphan Drug Rare Disease Market Highlighting Investment And Innovation Opportunities Through 2030 - Benzinga

06:19 AM
pulisher
05:31 AM

Jennison Associates LLC Makes New Investment in Gilead Sciences, Inc. $GILD - MarketBeat

05:31 AM
pulisher
01:31 AM

Gilead Sciences Announces Third Quarter 2025 Financial Results - BioSpace

01:31 AM
pulisher
12:13 PM

Gilead Sciences Reports Strong Q3 2025 Results - TipRanks

12:13 PM
pulisher
Oct 30, 2025

Gilead Sciences Inc (GILD) Q3 2025 Earnings Call Highlights: Strong HIV Sales Drive Growth ... - Yahoo Finance

Oct 30, 2025
pulisher
Oct 30, 2025

Gilead Sciences: Strong Financial Performance and Promising Growth Prospects Justify Buy Rating - TipRanks

Oct 30, 2025
pulisher
Oct 30, 2025

Gilead Sciences (GILD) Reports Strong Q3 2025 Performance - GuruFocus

Oct 30, 2025
pulisher
Oct 30, 2025

Gilead Sciences Inc (GILD) Q3 2025 Earnings Call Highlights: Str - GuruFocus

Oct 30, 2025
pulisher
Oct 30, 2025

Cell therapy sales dip 11% for Gilead, as HIV franchise drives quarter - Endpoints News

Oct 30, 2025
pulisher
Oct 30, 2025

Gilead Sciences’ HIV Drug Sales Lead A Strong Quarter - Finimize

Oct 30, 2025
pulisher
Oct 30, 2025

Gilead raises 2025 HIV revenue growth outlook to 5% as Biktarvy and Descovy drive momentum - MSN

Oct 30, 2025
pulisher
Oct 30, 2025

Gilead Sciences Lifts Forecast After Topping Earnings Expectations - Finimize

Oct 30, 2025
pulisher
Oct 30, 2025

Gilead Q3 2025 slides: HIV strength drives guidance raise, new products gain traction - Investing.com Nigeria

Oct 30, 2025
pulisher
Oct 30, 2025

Insider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells 10,000 Shares of Stock - MarketBeat

Oct 30, 2025
pulisher
Oct 30, 2025

Earnings call transcript: Gilead Sciences Q3 2025 beats expectations, stock steady - Investing.com

Oct 30, 2025
pulisher
Oct 30, 2025

Transcript : Gilead Sciences, Inc., Q3 2025 Earnings Call, Oct 30, 2025 - MarketScreener

Oct 30, 2025
pulisher
Oct 30, 2025

The Most Anticipated Gilead Drug Lagged Massive Expectations - Investor's Business Daily

Oct 30, 2025
pulisher
Oct 30, 2025

Gilead Sciences Dives As HIV Drug Misses Bullish Buy-Side Expectations - MSN

Oct 30, 2025
pulisher
Oct 30, 2025

Gilead (GILD) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance

Oct 30, 2025
pulisher
Oct 30, 2025

Gilead posts higher profit on demand for HIV drugs, but overall sales dip - Reuters

Oct 30, 2025
pulisher
Oct 30, 2025

Gilead Sciences (GILD) Surpasses Q3 Earnings Expectations - GuruFocus

Oct 30, 2025
pulisher
Oct 30, 2025

Gilead Sciences (GILD) Shares Fall Despite Beating Q3 Expectatio - GuruFocus

Oct 30, 2025
pulisher
Oct 30, 2025

Gilead Sciences Inc. Profit Advances In Q3 - Nasdaq

Oct 30, 2025
pulisher
Oct 30, 2025

Gilead Sciences (GILD) Surpasses Q3 2025 Earnings Expectations - GuruFocus

Oct 30, 2025
pulisher
Oct 30, 2025

Gilead Sciences Inc (GILD) Q3 2025 Earnings: EPS of $2.43 Beats Estimate, Revenue Reaches $7.8 Billion - GuruFocus

Oct 30, 2025
pulisher
Oct 30, 2025

Gilead drops despite narrowing 2025 outlook ranges on weak Veklury sales - MSN

Oct 30, 2025
pulisher
Oct 30, 2025

Earnings Snapshot: Gilead beats Q3 results but Veklury drags product sales - MSN

Oct 30, 2025
pulisher
Oct 30, 2025

Gilead Sciences (NASDAQ:GILD) Exceeds Q3 Expectations - Yahoo Finance

Oct 30, 2025
pulisher
Oct 30, 2025

Gilead Sciences Q3 Non-GAAP Earnings, Revenue Rise; 2025 Guidance Adjusted - MarketScreener

Oct 30, 2025
pulisher
Oct 30, 2025

Mich. Top Court Upholds Gilead Immunity In COVID Drug Case - Law360

Oct 30, 2025
pulisher
Oct 30, 2025

(GILD) Gilead Updates Full Year 2025 Product Sales Outlook Range To $28.40 Billion$28.70 Billion, vs. FactSet Est $28.71 Billion - MarketScreener

Oct 30, 2025
pulisher
Oct 30, 2025

Gilead Sciences misses on revenue guidance estimates, shares drop 4% - Investing.com

Oct 30, 2025
pulisher
Oct 30, 2025

(GILD) Gilead Sciences Updates Full Year 2025 Adjusted EPS Outlook Range To $8.05$8.25, vs. FactSet Est of $8.04 - MarketScreener

Oct 30, 2025

길리어드 사이언스 (GILD) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$294.11
price up icon 0.67%
drug_manufacturers_general PFE
$24.41
price up icon 0.37%
drug_manufacturers_general NVO
$48.98
price down icon 2.12%
drug_manufacturers_general SNY
$50.62
price down icon 0.55%
drug_manufacturers_general MRK
$84.64
price down icon 1.90%
자본화:     |  볼륨(24시간):